The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. The user inquires if RENU Biogen is a DHT inhibitor.
RU58841 slowed hair loss for a DUPA sufferer after other treatments like finasteride, dutasteride, and minoxidil failed. Some users reported side effects with RU58841, while others did not experience any.
This post and conversation are about the molecular mechanisms triggered by microneedling, specifically its effects on inflammation, tissue remodeling, epithelial proliferation, differentiation, and collagen synthesis. The discussion highlights the potential benefits of microneedling for hair loss treatment.
The conversation discusses skepticism about the effectiveness and formulation of a $10 RU58841 gel from a Korean brand, questioning if ethanol is used to hold the active compounds. Concerns are raised about the feasibility of selling it at such a low price.
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.
VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.
Low Dose Naltrexone (LDN) may reduce inflammation in alopecia conditions. It is discussed as a potential adjunct treatment with finasteride or dutasteride for androgenic alopecia.
An 18-year-old is seeking advice on microneedling while using RU58841 for hair loss. Recommendations include using a derma pen with 0.5mm needles every two weeks and avoiding RU application for 24 hours post-microneedling to prevent absorption into the bloodstream.
High DHEA levels may contribute to hair loss by increasing DHT in hair follicles, potentially explaining why finasteride is ineffective for some. Treatments like high-dose dutasteride and RU58841 are suggested, but the underlying cause, such as adrenal issues, should be investigated.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
Nanoxidil is considered to have better absorption and fewer side effects than minoxidil, with added DHT blockers. The user is questioning if switching to the more expensive Spectral.DNC-N is worthwhile compared to cheaper options like Kirkland minoxidil.
The conversation discusses the application of RU58841 for hair loss, with the user applying 1.75 mg at 5% concentration for half an hour daily. The user mentions managing seborrheic dermatitis while using this treatment.
Concerns about CosmeRNA safety mechanisms and potential side effects. Discussion includes comparisons to Fluridil and questions about nanoparticle specificity and siRNA stability.
A user recently started using nanoxidil 5% for hair loss, particularly on the hairline, and is seeking feedback or experiences from others. The conversation focuses on the effectiveness of nanoxidil.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.
The conversation discusses a hair loss treatment called "nanoxidil," which is similar to minoxidil but with better absorption. Users are curious about its effectiveness for hair regrowth.
The conversation is about a product called Serioxyl, which was expected to contain stemoxydine. It clarifies that Diethyl lutidinate is another name for stemoxydine.
The conversation discusses the potential effectiveness of a Sult1a1 enzyme booster in enhancing the results of minoxidil for hair loss. Users express interest in the booster, hoping it will improve the effectiveness of oral minoxidil, especially for those who struggle with topical application.
The conversation is about hair regrowth progress using a combination of treatments: dutasteride, minoxidil, RU58841, ketoconazole, and monthly microneedling. The user reports that microneedling and topical minoxidil had the most impact on their hairline.
Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. User asks about Redensyl's effectiveness, questioning if it's another ineffective remedy.
The conversation discusses concerns about the effectiveness of RU58841 due to high temperatures during delivery. A user reassures that the heat will not affect its efficacy.
The conversation is about making RU58841 solutions for hair loss treatment and sourcing ingredients for KB solutions. The user mentions using RU58841 powder from Shaanxi Greenyobiotech.
The conversation is about hair loss treatments, specifically discussing the use of dutasteride, minoxidil, and the potential benefits of a DNA test and PRP therapy. Opinions vary, with some users skeptical about the DNA test and PRP, suggesting sticking with current treatments.
RU-58642 is a powerful anti-androgen that was not developed further, possibly due to safety concerns or financial reasons. RU58841 is a topical alternative, but it is less effective than finasteride and dutasteride, and its long-term effects are not well-studied.
A Swiss product called Redensyl, which is supposed to target hair follicle stem cells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.